Skip to main content
Equibles

Farther Finance Advisors, LLC

Position in EXEL — Exelixis, Inc.

CIK 1992825 SAN FRANCISCO, CA
Back to EXEL Full portfolio

Position in EXEL

as of Sep 30, 2026 · filed Oct 8, 2026
Position Value
$1,068,318
+$297,274 QoQ
Shares Held
18,290
+29.1% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#3
of 26 holders
Holding Since
Dec 2022
16 quarters on record
Voting authority Sole 0% Shared 0% None 100%

Common Shares in EXEL Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Sep 30, 2026

Farther Finance Advisors, LLC holds $27,307,338 across 327 Biotechnology names. EXEL ranks #6 (3.9% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 9,471 $4,951,533
2 MRNA
Moderna, Inc.
 17,622 $3,393,468
3 HALO
Halozyme Therapeutics, Inc.
 11,074 $1,222,569
4 REGN
Regeneron Pharmaceuticals, Inc.
 1,534 $1,163,186
5 INCY
Incyte Corp
 9,256 $1,123,215
6 EXEL
Exelixis, Inc.
This page 		18,290 $1,068,318
7 RVMD
Revolution Medicines, Inc.
 4,848 $995,100
8 ARWR
Arrowhead Pharmaceuticals, Inc.
 12,147 $795,021

All Filings in EXEL

Export CSV
16 filing rows on record
Report Date Value (USD) Shares
2026-09-30 $1,068,318 18,290
2026-06-30 $771,044 14,171
2026-03-31 $705,240 16,443
2025-12-31 $760,801 17,358
2025-09-30 $714,448 17,299
2025-06-30 $868,816 19,710
2025-03-31 $198,334 5,372
2024-12-31 $168,664 5,065
2024-09-30 $102,243 3,940
2024-06-30 $15,594 694
2024-03-31 $15,638 659
2023-12-31 $15,449 644
2023-09-30 $1,682 77
2023-06-30 $917 48
2023-03-31 $194 10
2022-12-31 $160 10